Browsing by Author "Bast, Robert C., Jr."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
    (PLOS, 2020-06-04) Kim, Olga; Park, Eun Young; Klinkebiel, David L.; Pack, Svetlana D.; Shin, Yong-Hyun; Abdullaev, Zied; Emerson, Robert E.; Coffey, Donna M.; Kwon, Sun Young; Creighton, Chad J.; Kwon, Sanghoon; Chang, Edmund C.; Chiang, Theodore; Yatsenko, Alexander N.; Chien, Jeremy; Cheon, Dong-Joo; Yang-Hartwich, Yang; Nakshatri, Harikrishna; Nephew, Kenneth P.; Behringer, Richard R.; Fernández, Facundo M.; Cho, Chi-Heum; Vanderhyden, Barbara; Drapkin, Ronny; Bast, Robert C., Jr.; Miller, Kathy D.; Karpf, Adam R.; Kim, Jaeyeon; Biochemistry and Molecular Biology, School of Medicine
    Metastasis is responsible for 90% of human cancer mortality, yet it remains a challenge to model human cancer metastasis in vivo. Here we describe mouse models of high-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), the most common and deadliest human ovarian cancer type. Mice genetically engineered to harbor Dicer1 and Pten inactivation and mutant p53 robustly replicate the peritoneal metastases of human HGSC with complete penetrance. Arising from the fallopian tube, tumors spread to the ovary and metastasize throughout the pelvic and peritoneal cavities, invariably inducing hemorrhagic ascites. Widespread and abundant peritoneal metastases ultimately cause mouse deaths (100%). Besides the phenotypic and histopathological similarities, mouse HGSCs also display marked chromosomal instability, impaired DNA repair, and chemosensitivity. Faithfully recapitulating the clinical metastases as well as molecular and genomic features of human HGSC, this murine model will be valuable for elucidating the mechanisms underlying the development and progression of metastatic ovarian cancer and also for evaluating potential therapies.
  • Thumbnail Image
    Item
    Targeting progesterone signaling prevents metastatic ovarian cancer
    (National Academy of Science, 2020-12-15) Kim, Olga; Park, Eun Young; Kwon, Sun Young; Shin, Sojin; Emerson, Robert E.; Shin, Yong-Hyun; DeMayo, Francesco J.; Lydon, John P.; Coffey, Donna M.; Hawkins, Shannon M.; Quilliam, Lawrence A.; Cheon, Dong-Joo; Fernández, Facundo M.; Nephew, Kenneth P.; Karpf, Adam R.; Widschwendter, Martin; Sood, Anil K.; Bast, Robert C., Jr.; Godwin, Andrew K.; Miller, Kathy D.; Cho, Chi-Heum; Kim, Jaeyeon; Biochemistry and Molecular Biology, School of Medicine
    Effective cancer prevention requires the discovery and intervention of a factor critical to cancer development. Here we show that ovarian progesterone is a crucial endogenous factor inducing the development of primary tumors progressing to metastatic ovarian cancer in a mouse model of high-grade serous carcinoma (HGSC), the most common and deadliest ovarian cancer type. Blocking progesterone signaling by the pharmacologic inhibitor mifepristone or by genetic deletion of the progesterone receptor (PR) effectively suppressed HGSC development and its peritoneal metastases. Strikingly, mifepristone treatment profoundly improved mouse survival (∼18 human years). Hence, targeting progesterone/PR signaling could offer an effective chemopreventive strategy, particularly in high-risk populations of women carrying a deleterious mutation in the BRCA gene.